Moderna (MRNA)
Nasdaq Market Closed
Moderna, Inc. is a biotechnology company built around messenger RNA, or mRNA, medicines. The company became globally known after its COVID-19 vaccine demonstrated the speed and scalability of mRNA technology, moving Moderna from a platform-stage biotech into a commercial vaccine producer.
Moderna continues to apply mRNA across infectious disease, oncology, rare genetic disease and other therapeutic areas. Its research model uses mRNA instructions to direct cells to produce proteins that can trigger immune responses or address disease biology. The company’s pipeline includes multiple clinical programs, and its commercial prospects depend on vaccine demand, new product approvals and the ability to extend mRNA beyond COVID-19. MRNA is therefore both a biotech platform investment and a test of how broadly mRNA medicines can be commercialized.
Last updated
- Market Cap
- $27,092,565,765
- P/E
- —
- P/FCF
- —
- P/S
- 12.18
- Enterprise Value
- $25,787,565,765
- Sector
- Health Care
- Industry
- Biotechnology
- Address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
US Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom
Is it easier to become a stock picker in a stock picker's market?
Stock Market Today: Dow Ends Higher; SK Hynix Jumps In U.S. Trading Debut; Moderna Tumbles
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
US Stock Market Today: S&P 500 Futures Fall On Higher Yields And Inflation Jitters
Update: Dow Logs Worst Day in 4 Weeks Amid Renewed US-Iran Tensions
Moderna Stock Is Soaring. Is It Too Late to Buy?
US Stock Market Today: S&P 500 Futures Rise As Inflation Jitters Temporarily Ease
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna”
Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
CytomX Therapeutics to Present at Upcoming June Investor Conferences
Hantavirus outbreak: these 3 stocks are poised to rip higher
Moderna stock soars as hantavirus fears spark outbreak trade
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $27,092,565,765
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $25,787,565,765
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.66
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 12.18
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -8.12
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 11.59
- EPS
- -8.05
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$1,603,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -43.12%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -27.8%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.08
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.41
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.35
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.8
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $8,707,859
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 68.28
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 389M | 678M | 1.02B | 142M | 108M |
| Cost of revenue | 955M | 452M | 207M | 119M | 90M |
| Gross profit | -566M | 226M | 809M | 23M | 18M |
| Operating income | -1.39B | -857M | -260M | -907M | -1.05B |
| EBITDA | -1.33B | -790M | -208M | -850M | -1.01B |
| Net income | -1.34B | -826M | -200M | -825M | -971M |
| Income taxes | 9M | 27M | 13M | 7M | 7M |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 822M | 1.08B | 1.07B | 930M | 1.07B |
| Basic EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 |
| Diluted EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 11.49B | 12.34B | 12.14B | 12.01B | 12.7B |
| Total liabilities | 4.08B | 3.69B | 2.81B | 2.61B | 2.64B |
| Total equity | 7.41B | 8.65B | 9.33B | 9.4B | 10.07B |
| Cash & equivalents | 1.91B | 2.6B | 1.13B | 1.28B | 1.62B |
| Current assets | 5.77B | 6.54B | 6.6B | 6.17B | 6.77B |
| Current liabilities | 2.4B | 1.99B | 1.68B | 1.57B | 1.6B |
| Accounts payable | 161M | 317M | 267M | 175M | 226M |
| Receivables | 71M | 184M | 1.05B | 36M | 78M |
| Inventories | 146M | 153M | 332M | 240M | 128M |
| Long-term debt | 603M | 610M | 26M | 32M | 35M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -630M | 930M | -847M | -919M | -1.04B |
| Investing cash flow | -76M | -48M | 700M | 564M | 730M |
| Financing cash flow | 17M | 581M | -1M | 9M | 4M |
| Change in cash | -688M | 1.46B | -147M | -345M | -303M |
| Net income | -1.34B | -826M | -200M | -825M | -971M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — Moderna, Inc. | View Filing | |
| edgar index | 3 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 8-K — Moderna, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Banque Soria Ester | View Filing | |
| form 4 | Form 4 — Banque Soria Ester | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| edgar index | 3 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free